Novel Perspectives in Pseudomyxoma Peritonei Treatment
Open Access
Abstract
Pseudomyxoma Peritonei (PMP) is an anatomo-clinical condition characterized by the implantation of neoplastic cells on peritoneal surfaces with the production of a large amount of mucin. The rarity of the disease precludes the evaluation of treatment strategies within randomized controlled trials. Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has proven to be the only therapeutic option with potential chances of cure and long-term disease control. The present review discusses the epidemiology, pathogenesis, clinical presentation and treatment of PMP, focusing on the molecular factors involved in tumor progression and mucin production that could be used, in the upcoming future, to improve patient selection for surgery and to expand the therapeutic armamentarium.Keywords
This publication has 112 references indexed in Scilit:
- Immunotoxins: The Role of the ToxinToxins, 2013
- Properties and Therapeutic Application of Bromelain: A ReviewBiotechnology Research International, 2012
- Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trialLeukemia, 2010
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapyJournal of Hematology & Oncology, 2010
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivoBritish Journal of Cancer, 2009
- Pseudomyxoma Peritonei: A Need to Establish Evidence-Based Standard of Care—Is This the Right Trial?Annals of Surgical Oncology, 2009
- A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritoneiBritish Journal of Cancer, 2008
- Appendiceal neoplasms and pseudomyxoma peritonei: A population based studyEuropean Journal of Surgical Oncology, 2008
- A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritoneiBritish Journal of Cancer, 2006